10 mg lyophilised · single compound
$85.00 CAD
TB-500 is a synthetic version of the active part of a natural repair protein, widely studied alongside BPC-157 in recovery research. Studies look at its role in cell movement, blood-vessel formation, and tissue healing.
For laboratory and research use only - not for human consumption.
Checking the live COA archive for the newest lot documentation.
Use the verification archive to select a peptide name and review all published lot records alphabetically.
View previous lab resultsTB-500 is a synthetic peptide based on the active region of Thymosin Beta-4, a natural protein that is the body’s main “actin-sequestering” molecule (actin is the protein that builds the cell’s internal scaffolding and lets cells move).
Foundational studies of Thymosin Beta-4 showed it speeds wound closure, promotes angiogenesis (new blood vessels), and drives cell migration - in rodent wound models it increased re-epithelialisation (skin resurfacing) markedly. TB-500 is frequently studied alongside BPC-157 in tissue-repair research.
By regulating actin, it helps cells reorganise their internal scaffolding to migrate into and repair injured areas, while supporting new blood-vessel formation.
TB-500 is not an approved medicine in any jurisdiction, and this product is supplied as a research compound only. In July 2026 a US FDA advisory committee voted 8-6-1 to recommend TB-500 for the American 503A compounding list, having reviewed it for wound healing and against the recommendation of the FDA's own scientific reviewers. That vote is advisory and not binding: it concerns what US compounding pharmacies may work with, it is not a drug approval, and it takes effect only if the FDA accepts it and completes formal rulemaking.
A single vial containing 10 mg of TB-500 as a lyophilised powder.
